A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin

Topical rapamycin is used to reduce facial angiofibromas in patients with tuberous sclerosis (TSC). In the absence of a commercially available preparation, numerous formulations have been tested clinically, although only in the short term. The pharmacy at Angers University Hospital (France) produced...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annales de dermatologie et de vénéréologie 2023-12, Vol.150 (4), p.270-273
Hauptverfasser:	Sigg, N., Fouquet, J., Morin, D., Farges, D., Vrignaud, S., Martin, L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiofibroma - complications Angiofibroma - drug therapy Angiofibromas Drug survival Facial Neoplasms - drug therapy Facial Neoplasms - etiology Humans Immunosuppressive Agents - therapeutic use Rapamycin Sirolimus - adverse effects Tuberous Sclerosis - complications Tuberous sclerosis complex
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!